Myfortic® -
A recommended MPA-based therapy fulfilling the need for post-transplant care1
-
Either mycophenolate sodium (Myfortic®) or mycophenolate mofetil (MMF) is recommended as part of standard initial immunosuppressive regimen, along with other agents
-
The regimen is given to most patients and provides excellent efficacy with good tolerability.1
Supporting sustained adherence through reduced GI-related dose reductions and treatment discontinuations2-4
Allowing an increase in MPA dose while reducing GI complications when switching from MMF to Myfortic®4
Lowering the incidences of acute kidney rejection and BPAR vs MMF3
Abbreviations:
GI: gastrointestinal; MMF: mycophenolate mofetil; MPA: mycophenolic acid; BPAR: biopsy-proven acute rejection
References:
1. EAU Guidelines on Renal Transplantation 2025. Available at https://uroweb.org/guidelines/renal-transplantation. Accessed May 2025 2. Chan L, et al. Transplantation. 2006;81(9):1290-1297. 3. Sollinger HW, et al. Transplantation. 2010;89(4):446-451. 4. Ortega F, et al. Transplantation. 2011;92:426-432.
20 Pasir Panjang Road #10-25/28 Mapletree Business City (West Tower) Singapore 117439
Phone: +65 6722 6010
This content is not for local distribution. This should be modified to accommodate local guidance before local distribution.
FOR HEALTHCARE PROFESSIONALS ONLY
Please visit https://www.novartis.com/sg-en/product-list/myfortic to access or download the Package Insert.
Alternatively, please scan this code for more Information about this medicine.
FA-11484255_2027Aug05